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The striatum is particularly vulnerable to neurological disor-
ders, such asHuntingtondisease. Previous studies,withnonsyn-
aptic mitochondria isolated from cortical and striatal homoge-
nates, suggest that striatal mitochondria are highly vulnerable
to Ca2 loads, possibly influencing striatal vulnerability. How-
ever, whether and how neuronal and glial mitochondria from
cortex and striatum differ in Ca2 vulnerability remains
unknown. We test this hypothesis using a novel strategy allow-
ing comparisons of mitochondrial Ca2 buffering capacity in
cortical and striatal neuron-astrocyte co-cultures. We provide
original evidence thatmitochondria not only inneuronsbut also
in astrocytes from striatal origin exhibit a decreased Ca2 buff-
ering capacity when compared with cortical counterparts. The
decreasedmitochondrial Ca2 buffering capacity in striatal ver-
sus cortical astrocytes does not stem from variation in mito-
chondrial concentration or in the rate of intracellular Ca2 ele-
vation, being mechanistically linked to an increased propensity
to undergo cyclosporin A (CsA)-sensitive permeability transi-
tion. Indeed, 1 M CsA selectively increased the mitochondrial
Ca2buffering capacity of striatal astrocytes,withoutmodifying
that of neurons or cortical astrocytes. Neither thapsigargin nor
FK506 modified mitochondrial Ca2 buffering differences
between cell types, excluding a predominant contribution of
endoplasmic reticulum or calcineurin. These results provide
additional insight into the mechanisms of striatal vulnerabil-
ity, showing that the increased Ca2 vulnerability of striatal
versus cortical mitochondria resides in both intact neurons
and astrocytes, thus positioning the striatum at greater risk
for disturbed neuron-astrocyte interactions. Also, the selec-
tive effect of CsA over striatal astrocytes suggests that in vivo
neuronal sheltering with this compoundmay indirectly result
from astrocytic protection.
Brain regions and cell types vary in their susceptibility to
neurological disorders. The striatum is particularly vulnerable
to both acute (e.g. hypoglycemia, hypoxia, and global ischemia)
and chronic (e.g. Huntington disease (HD)2) disorders. Excito-
toxicity and altered energy metabolism have been proposed as
important determinants of striatal pathogenesis, leading to
toxic increases in [Ca2]i (1). Studies with mitochondria iso-
lated from brain homogenates raised the hypothesis that stria-
tal mitochondria are more vulnerable to Ca2 loads than corti-
cal mitochondria, possibly contributing to selective striatal
vulnerability in pathologies such as HD (2). However, because
isolated mitochondria are deprived from its physiological cel-
lular context, and brain homogenates contain mitochondria
from both neurons and glia, two fundamental questions remain
unanswered: first, whether the differences in Ca2 vulnerabil-
ity, observed with isolated mitochondria, also occur in situ (i.e.
when mitochondria are in their physiological environment
inside intact cells) and, second, whether mitochondrial vulner-
ability to Ca2 loads differs among neurons and glia from cor-
tex and striatum.
Striatal selectivity in HD is noteworthy, given that the dis-
ease-causing protein (mutant huntingtin) is widely expressed
throughout the brain and not enriched in the striatum (3).
Although HD may also affect nonstriatal regions, namely the
cortex (4), typical striatal atrophy and neuronal loss greatly
exceed those seen in nonstriatal regions, particularly when HD
is not superimposed with Alzheimer’s disease or age-related
volumetric loss (5). This suggests that vulnerability factors
inherent to striatal neurons shape the selective pattern of HD
neurodegeneration. One likely factor is the enrichment in
N-methyl-D-aspartate (NMDA) receptors containing NR2B
subunits, allowing prolonged Ca2 influx following excitotoxic
stimuli (6), but other vulnerability factors may assist. Mito-
chondria have an essential role in neuronal survival following
excitotoxic [Ca2]i elevations (7), and mitochondria-depend-
entCa2handling is impaired in striatal neurons fromHDmice
(8). HDmay in fact be aggravating inherent mitochondrial vul-
nerability in the striatum,whichmay reside in either neurons or
glia. Indeed, glia may also contribute for non-cell-autonomous
neurodegeneration in HD (9) or ischemic injuries (10, 11), thus
stressing the importance of identifying vulnerability factors in
both neurons and glia.
In the present study, we test the hypothesis that mitochon-
drial vulnerability to Ca2 loads differs among intact neurons
and astrocytes from cortex and striatum.We prepared primary
neuron-astrocyte co-cultures from rat cortex and striatum,
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whose cellular composition and functional differentiation were
confirmed by immunolabeling and functional imaging studies,
respectively. Here we report for the first time not only the
development but also the application of an experimental strat-
egy allowing comparisons of in situ mitochondrial Ca2 buff-
ering capacity in the preserved physiological context of intact
brain cells. To allow balanced comparisons, similarly to standard
procedures with isolated mitochondria experiments, we have
introduced calibrations for differences in mitochondrial concen-
tration and rate of intracellular Ca2 elevation in intact cells.
Results in the present study provide additional insight into
the mechanisms of striatal vulnerability, showing for the first
time that the increased vulnerability of striatal mitochondria to
Ca2 loads is present in both intact neurons and astrocytes
when compared with their cortical counterparts. Interestingly,
our finding of a lowermitochondrial Ca2 buffering capacity in
intact striatal versus cortical astrocytes, mechanistically linked
to increased cyclosporin A-dependent permeability transition,
positions the striatum at higher risk for disturbed interactions
between two synaptic partners, neurons and astrocytes.
EXPERIMENTAL PROCEDURES
Materials—Fura-4F acetoxymethyl ester, tetramethylrhoda-
mine methyl ester (TMRM), and 4-bromocalcimycin were
from Invitrogen. Plasmamembrane potential indicator (PMPI)
(Component A from the R-8042 membrane potential assay kit)
was from Molecular Devices Corp. (Sunnyvale, CA) (12). Cul-
ture media and supplements were from Invitrogen unless oth-
erwise stated. NMDA, (5R,10S)-()-5-methyl-10,11-dihy-
dro[a,d]cyclohepten-5,10-imine hydrogen maleate (MK-801),
ifenprodil, myxothiazol, oligomycin B, rotenone, carbonylcya-
nide-p-(trifluoromethoxyphenyl) hydrazone (FCCP), cyclos-
porin A, tacrolimus (FK506), thapsigargin, and other reagents
were from Sigma.
Cell Culture—Primary cultures were generated from the off-
spring ofWistar rats (CRIFFA, Barcelona, Spain). Handling and
care of animals were conducted according to the European
Union guidelines for animal research (86/609/EEC; in agree-
ment with the National Institutes of Health guidelines) and
Portuguese law (Portarias 1005/92 and 1131/97). Cortical and
striatal cultures were prepared and maintained as previously
described for striatal cultures (8, 13) butwithout cytosine arabi-
noside to allow the growth of astrocytes. Briefly, hemicortices
(free from meninges, olfactory bulb, striatum, and hippocam-
pus) and hemistriata were dissected from the same embryonic
day 18 rats, pooled according to brain region (cortex or stria-
tum), and processed in parallel (sister cultures). Dissociated
cells (1 105) were plated in 12-mm round polyethyleneimine-
coated glass coverslips and used in functional imaging experi-
ments between 11 and 13 days in vitro (DIV).
Immunocytochemistry—Cells were fixed with 4% paraform-
aldehyde for 15 min at 37 °C and permeabilized with 0.4% Tri-
ton X-100 in phosphate-buffered saline for 15 min. Blocking
was performed with 3% bovine serum albumin in phosphate-
buffered saline for 30min at room temperature. Cells were then
incubated with primary antibodies for the neuronal marker
(mouse anti-MAP-2 (microtubule-associated protein); Sigma;
1:500) and the astrocytic marker (rabbit anti-glial fibrillary
acidic protein (GFAP); Dako; 1:250) in 3% bovine serum albu-
min phosphate-buffered saline for 1 h at room temperature.
Afterwashing, cells were incubatedwith appropriate secondary
antibodies conjugated to either AlexaFluor 488 or 594 (Invitro-
gen; 1:200) for 1 h at room temperature and shielded from light.
Nuclei labelingwas performedwithHoechst 33342 (Invitrogen;
2 g/ml; 10 min at room temperature). To test for antibody
selectivity, primary antibodies were omitted in control coverslips
processed in parallel. No immunolabelingwas observed in control
coverslips, which were used for shading correction of epifluores-
cent images, acquired with the same equipment settings.
Monitoring of Dynamic Changes in [Ca2]i, Mitochondrial
Membrane Potential (m), and Plasma Membrane Potential
(p) in Single Cells—Functional imaging at single-cell resolu-
tion was performed with a system composed by an inverted
epifluorescence microscope (Eclipse TE300, Nikon, Tokyo,
Japan) equipped with 20, 40, and 60 air objectives, a
monochromator (Polychrome II; TILL Photonics, Martinsried,
Germany), a CCD camera (C6790; Hamamatsu Photonics,
Hamamatsu, Japan), and a computer with analysis software
(Aquacosmos 2.5; Hamamatsu Photonics). Cells were loaded
with the [Ca2]i probe Fura-4F (5 M) for 45 min at 37 °C. For
simultaneous recordings of changes in [Ca2]i and in TMRM
fluorescence (indicative of changes in m), 50 nM TMRM
(quench mode) (14). was present during Fura-4F loading and
throughout the experiments. Simultaneous recordings of
changes in [Ca2]i and in p were performed in Fura-4F-
loaded cells with a constant PMPI concentration present
throughout the experiment. The PMPI concentration was the
same as previously described (12), corresponding to a 1:2,000
dilution of a PMPI stock solution prepared by reconstituting
one R-8042 Component A vial in 1 ml of ultrapure water.
Experiments were performed at 37 °C in buffer containing 133
mM NaCl, 5 mM KCl, 1 mM Na2SO4, 0.4 mM KH2PO4, 20 mM
HEPES, 1.3 mMCaCl2, and 15mM glucose, pH 7.4.Where indi-
cated, glucose was replaced by 2 mM 2-deoxy-D-glucose, and
mitochondria were energized with 10 mM pyruvate. Fura-4F
was excited at 340 and 380 nm, TMRM at 550 nm, and PMPI
at 500 nm. Dual Fura-4F and TMRM emission was collected
with a 73100bs dichroic and a 73101m emitter (Chroma Tech-
nology Corp., Rockingham, VT), whereas dual Fura-4F and
PMPI emission was collected with a 505-nm beam splitter and
a 520-nm long pass filter. There was no significant bleed-
through between Fura-4F and TMRM or between Fura-4F
and PMPI with these excitation and emission settings. Individ-
ual cells were identified as regions of interest (ROIs) for the
determination of fluorescence time courses.
In situ calibration of Ca2 responses for each individual cell
was performed at the end of every experiment, according to
previously detailed procedures (8). Briefly, maximal 340/380
ratios (Rmax) were determined with 20 M 4-bromocalcimycin
with 1.3 mM extracellular Ca2, and minimal 340/380 ratios
(Rmin) were determined in Ca2-free buffer with 5 mM EGTA.
This Ca2-free buffer contained neither TMRM nor PMPI,
and thus the subsequent decays in their respective fluorescence
should not be interpreted as changes in m or p. In exper-
iments addressing mitochondrial Ca2 buffering capacity,
maximalmitochondrial depolarization (m collapse)was con-
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firmed/evoked before [Ca2]i calibration by adding protono-
phore (1 M FCCP), with ATP synthase reversal prevented by
oligomycin (3 M). Further details on the analysis of cellular
responses are provided below.
Image Processing and Data Analysis—Analysis of [Ca2]i
responses was performed as previously detailed (8). Briefly,
background-corrected 340/380 Fura-4F ratioswere normalized
to the Rmax (100 units) and Rmin (0 units) determined for each
single cell during in situ calibration. The left yy axes of Ca2
graphs are scaled with these normalized values, where 50 units
should correspond to the Ca2 probeKd, regardless of its abso-
lute value inside the different cells. The right yy axis is an
approximate log [Ca2]i scale adjusted based on the dynamic
range of Fura-4F and Kd determinations (15, 16).
Changes in TMRM and PMPI fluorescence in single cells
are expressed as arbitrary fluorescence units. Individual sig-
nals are corrected for epifluorescence shading, using images
acquired in the same experimental xx-yy-zz plane, without
TMRM (during Rmin determination at the end of the experi-
ment) and in the absence of PMPI (before starting the experi-
ment, in PMPI-free buffer). Exposure times for image acquisi-
tion were kept constant in all experiments, with signal
saturation and underexposure being avoided merely by adjust-
ing camera gain before starting the experiments. Mathematical
correction for different gains was introduced so that all fluores-
cent signals are compared under the same circumstances.
Conversions tomVof neuronal PMPI fluorescence (Figs. 1,B
and D (ii), and 2, A (ii)) were performed in a manner similar to
that described previously (12) but with in situ calibration for
each individual neuron. Briefly, extracellular Nawas replaced
equimolarly by K in a stepwise fashion, up to 42 mM extracel-
lular K in the assay buffer. p values (in mV) were derived
from the Goldman-Hodgkin-Katz equation, assuming conduc-
tances for K, Na, and Cl of 100:1:100. PMPI fluorescence
enhancements evoked by K in each neuron were plotted in a
function of p and fit monoexponentially (correlation coeffi-
cients, r2  0.990) to generate individual calibration curves to
derive approximate p changes in mV.
Cell size was determined from the ROI area (m2) using
micrometer-calibrated images. Neuronal areas reflect only the
soma,due to impossibilityof tracing theentireneuronalprocesses.
Area conversion into approximate somatic diameter (e.g. Fig. 2B)
was performed by a circular approximation using Equation 1,
d  2  SQRTa/ (Eq. 1)
where d represents the diameter, SQRT is the square root, a is
the area, and  is the circular constant.
Mitochondrial concentration in single cells was estimated
from the analysis of the average TMRM fluorescence in
each ROI (for a representative measurement, see Fig. 3A (ii),
solid line,   ). The difference between resting TMRM
fluorescence (start of experiment) and nonmitochondrial
fluorescence (TMRM signal after FCCP, prior to Rmax
determination; Figs. 3 and 4 (ii), solid lines) was assumed to
reflect mitochondrial concentration. Our assumption is
based on evidence that when the amount of TMRM stacked
in the mitochondria surpasses the quench threshold, auto-
quenching occurs and fluorescence becomes invariant with
matrix TMRM concentration (14); TMRM quenching in
the present study is evidenced by the dequenching spikes in
Fig. 4, A–D, ii, solid lines). Therefore, the resting cellular
TMRM fluorescence in our experiments is primarily gov-
erned by the amount of mitochondria per cell volume (mito-
chondrial concentration) with superimposed nonmitochon-
drial fluorescence. This nonmitochondrial fluorescence
reflects TMRM in extracellular buffer in the cytosol and non-
specifically bound to cellular elements. Hence, subtracting the
residual TMRM signal following full m collapse (as con-
firmed with FCCP in the presence of oligomycin) should elim-
inate the vast majority of nonmitochondrial fluorescence, thus
yielding an estimate of mitochondrial concentration. We fur-
ther substantiate this procedure by providing bothmediumand
high magnification images (supplemental material) of
TMRM-loaded neurons and astrocytes used in functional
experiments. Collectively, the images show that the mitochon-
drial distribution is sparser in astrocytes that in neurons, visu-
ally showing a lower mitochondrial concentration. We also
provide fluorescence intensity profiles across representative
cells as well as time lapse experiments illustrating how m
collapse with oligomycin plus FCCP influences TMRM distri-
bution and fluorescence intensity values in mitochondria-rich
and mitochondria-free cellular regions.
The rate of [Ca2]i elevation was estimated by curve-fitting
(with nonlinear regression) the normalized Fura-4F 340/380
ratios in experiments such as in Fig. 4, where the combination
of oligomycin and a respiratory chain inhibitor (myxothiazol)
collapsed m, preventing mitochondrial Ca2 uptake (17).
Best fit values, with r2 0.990, were obtained with Equation 2,
y  IF 	 x0, THEN y b, ELSE y b
 t b
 1 eKexp  x x0 (Eq. 2)
where y represents normalized [Ca2]i at time x, x0 is the first time
point,b isbasal [Ca2]i, t is the toppartof thecurve (constrained to
bebelowthe100valueachievedduringRmax), e isNeper’snumber,
and Kexp is the exponential constant used to compare the rate of
[Ca2]i elevationamongcells (e.g.Fig. 4A (i),Kexparrow). It should
be noted that myxothiazol, albeit at higher concentrations, was
previously shown to inhibit Ca2 influx through store-operated
channels (18). However, 3M oligomycin (specifically oligomycin
B,whichhas a0.5MK50 for the inhibitionof store-operatedCa2
influx (19)) was present in our experiments either with or without
myxothiazol, thus preventing differences in store-operated Ca2
influx between these experiments.
Image processing was performed with Aquacosmos 2.5
(Hamamatsu Photonics) and with ImageJ (National Institutes of
Health; available on the World Wide Web). Calculations on
numerical data derived from ROIs were automated in Excel
spreadsheets (Microsoft Corp., Redmond, WA). Values through-
out are presented asmean S.E. unless otherwise stated. Nonlin-
ear regressions, curve fitting, and t tests were performed using
GraphPad Prism version 4.0 (San Diego, CA). Other statistical
analyses were performed with Statistical Package for the Social
Sciences version15.0 forWindows (SPSS Inc.,Chicago, IL).Type I
error probability was set at 0.05 for all analyses.
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RESULTS
CharacterizationofNeuronsandAstrocytes inCortical andStri-
atal Cultures—Immunolabeling revealed that cortical and stri-
atal cultures were predominantly composed of neurons and
astrocytes (over 95% of all nuclei stained with Hoechst 33342
were also positive for either the neuronal marker, MAP-2, or
the astrocytic marker, GFAP) (supplemental Fig. 1). At 11 DIV,
cells were functionally differentiated. Neurons responded to
K or NMDA receptor (NMDAR) activation with [Ca2]i ele-
vationandplasmamembranedepolarizationinaconcentration-
dependent manner (Fig. 1, A and C, and solid lines in B and D).
In contrast, astrocytes did not respond to NMDA (up to 100
M), despite exhibiting changes in plasma membrane polariza-
tion upon K challenging. Also, no changes in astrocytic
[Ca2]iwere detected during either K or NMDA challenging,
despite clear responses to Ca2-ionophore during [Ca2]i cal-
ibration (Rmax; Fig. 1, A and C, and dashed lines in B and D).
These clear functional differences ensured cellular identifica-
tion, particularly in experiments with PMPI (e.g. Fig. 1,A andC
(ii), bottom left; Fig. 3, A and B (ii), dashed lines).
To appraise differences between cortical and striatal neu-
rons, we integrated three parameters (somatic diameter,
NMDA pEC50, and proportion of functional NMDAR-2B) in a
cluster analysis with n	 23 random neurons of each type. The
average somatic diameter was larger for cortical neurons
(17.4  0.4 versus 12.9  0.2 m; p 
 0.001). Despite similar
FIGURE 1.Neurons and astrocytes are functionally differentiated in both cortical and striatal cultures. A and C, field excerpts from 20 photos of 11 DIV
cortical and striatal cultures, respectively, used in functional imaging experiments with simultaneous recordings of changes in [Ca2]i with Fura-4F and p
with PMPI. Scale bar, 20 m. B and D, functional [Ca2]i (i) and p (ii) responses of single representative neurons (solid lines) and astrocytes (dashed lines)
exposed to the indicated concentrations of KCl and NMDA/glycine (10:1). Data are from a representative experiment with sister cortical and striatal cultures.
Time bar, 5 min.
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NMDA pEC50 (5.48  0.05 versus 5.36  0.05, cortical and
striatal neurons, respectively; p 	 0.087), the contribution of
the NMDAR-2B subtype for [Ca2]i responses was higher in
striatal (37.0 2.1%) versus cortical neurons (24.9 1.9%; p

0.001). This latter parameter was derived from the degree of
attenuation with ifenprodil (2M; selective NMDAR-2B antag-
onist; IFEN in Fig. 2A) of plateau responses to 10 MNMDA (a
concentration close to the NMDA EC50) and is expressed as a
percentage of maximal attenuation with MK-801 (5 M; non-
subtype-selective NMDAR antagonist). These three parame-
ters were plotted three-dimensionally, and a “two-step cluster
analysis” (Statistical Package for the Social Sciences version
15.0; blind to both the cortical or striatal origin of the data
points as well as the expected number of clusters) separated
them into two clusters (Fig. 2B, red dashed line), nearly com-
pletely (40:46) matching their brain origin and thus showing
strong differences among the two neuronal populations.Mean-
ingfully, these differences are reminiscent of the in vivo condi-
tion, namely the smaller somatic size of striatal neurons and
particularly their higher proportion of functional NMDAR-2B,
which is considered a relevant determinant for their selective
vulnerability (6, 20).
Interestingly, three-dimensional cluster analysis with mor-
phofunctional parameters also separated neurons and astro-
cytes with minor overlap (supplemental Fig. 2), showing the
potential application of this strategy to automated image anal-
ysis. Most importantly, evidence of morphological and func-
tional differences among cells underlines the significance of
comparing their mitochondrial properties in situ.
In SituMitochondrial Ca2BufferingCapacity in IntactNeu-
rons and Astrocytes—To monitor mitochondrial Ca2 buffer-
ing in situ, cells were loaded with Fura-4F (Kd 1 M), a probe
we have previously shown adequate to identify the mitochon-
drial set point for Ca2 accumulation (8). Because we aimed as
studying intact cells, we avoided standard strategies such as
ionophores or proteolytic enzymes as a means to expose mito-
chondria to Ca2. Instead, we devised a strategy using a con-
trolled ATP depletion to elevate [Ca2]i, which was buffered at
the expense of m by mitochondria energized with the cell-
permeable substrate pyruvate (10 mM).
To initiate the Ca2 challenging of in situmitochondria, gly-
colytic and mitochondrial ATP generation were prevented by
replacing glucosewith 2-deoxy-D-glucose (2mM) and by adding
the ATP synthase inhibitor oligomycin (3 M). This procedure
initiated an elevation of [Ca2]i in both neurons and astrocytes
(Fig. 3, A–D, i, O), reaching a “plateau” (Fig. 3A (i),  point),
after which [Ca2]i was buffered for a variable period until the
onset of a massive increase in [Ca2]i (Fig. 3A (i),  point),
suggesting widespread Ca2 overload in the in situ mitochon-
drial population of each single cell, which invariably led to cell
death.
Evidence that the above described [Ca2]i plateau results
frommitochondrial Ca2 buffering is as follows: (i) the plateau
occurs at [Ca2]i close to the mitochondrial set point for Ca2
accumulation (0.3–1 M) (7) (Fig. 3, A–D (i)); (ii) no plateau is
observed if mitochondria are prevented from uptaking Ca2
(Fig. 4, A–D (i)); (iii) the plateau is immediately disrupted, and
mitochondrial Ca2 is released to the cytosol, upon m col-
lapse with protonophore (1 M FCCP) (supplemental Fig. 3B);
(iv) mitochondrial depolarization, as judged from the analysis
of TMRM redistribution (Fig. 3,A–D (ii), solid lines), is ongo-
ing throughout the [Ca2]i plateau and near completion at the
time where the plateau can no longer be sustained (Fig. 3, 
point).
Measurements of in situmitochondrial Ca2 buffering were
thus derived from the time difference between the aforemen-
tioned and points (	 duration of the [Ca2]i plateau),
a procedure that follows the same reasoning applied to isolated
FIGURE 2.Cultured cortical and striatal neurons aremorphologically and
functionally distinct. A, simultaneous monitoring of changes in [Ca2]i (i)
and p (ii) in cortical and striatal neurons. NMDA (10 M  1 M glycine),
ifenprodil (IFEN; 2 M), and MK-801 (5 M) were added where indicated.
Matched color lines in i and ii representmeasurements performed in the same
representative neuron (three are shown for each type). Time bar, 2 min.
B, three-dimensional morphofunctional clustering of cortical (black circles)
and striatal (white circles) neurons using the three parameters in xx, yy, and zz.
Data are from a total of 46 (23 cortical and 23 striatal) neurons from single
representative experiments with sister cultures. The solid lines converge to
the respective centroid, and the vertical red dashed line divides neurons
according to the blinded “two-step cluster analysis.”
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mitochondria experiments with steady Ca2 infusion (13,
21). Results for the duration of the [Ca2]i plateau are shown
in Fig. 5A, where a two-factor (region  cell type) ANOVA
revealed a significant region cell type interaction (F(1,24)	
4.63; p 	 0.042), a significant main effect of the cell type
(neurons versus astrocytes; F(1,24)	 23.7; p
 0.001), and no
significant effect of the brain region (cortical versus striatal;
F(1,24) 	 1.23; p 	 0.279).
These results, per se, suggest that in situmitochondrial Ca2
buffering capacity is higher in neurons than in astrocytes, with
no differences between cortical and striatal neurons, and with
mitochondria in striatal astrocytes exhibiting the lowest Ca2
buffering capacity, thus affording the lowest protection and
precipitating loss of Ca2 homeostasis and cell death. Still, fol-
lowing a similar reasoning to standard isolated mitochondria
experiments, we investigated whether differences inmitochon-
drial concentrations and/or rate of Ca2 elevation among cell
types might be influencing these results.
Mitochondrial Concentration and Rate of [Ca2]i Elevation
in Intact Neurons and Astrocytes—Because the cellular mito-
chondrial concentration, and the rate of [Ca2]i elevation may
affect the time during which intact cells can buffer [Ca2]i
(more mitochondria or less Ca2 	more time; less mitochon-
dria or more Ca2	 less time), we have assessed whether such
parameters differ among neurons and astrocytes from cortical
and striatal origin. Mitochondrial concentrations were meas-
ured as detailed under “Experimental Procedures” (e.g.   in
Fig. 3A (ii), solid line; see also supplemental material). Analysis
of TMRM fluorescence under matrix quenching conditions
(50 nM; as demonstrated by the dequenching spikes in Fig. 4,
A–D (ii), solid lines) revealed a higher mitochondrial concen-
tration in neurons than in astrocytes, expressed by a larger dif-
ference between the TMRM fluorescence before oligomycin
and that remaining after FCCP, which reflects nonmitochon-
drial fluorescence (Figs. 3 and 4,A andC (ii) versus B andD (ii),
solid lines). Two-factor (region  cell type) ANOVA of the
mitochondrial concentration (Fig. 5B) revealed a significant
main effect of the cell type (neurons versus astrocytes; F(1,16)	
24.5; p
 0.001) and no significant effect of brain region (corti-
cal versus striatal; F(1,16)	 1.11; p	 0.308) nor of region cell
type interaction (F(1,16) 	 0.253; p 	 0.622). Hence, these
results suggest that the lower “apparent” mitochondrial Ca2
buffering capacity for astrocytes (Fig. 5A) is partly due to their
lower mitochondrial concentration, when compared with neu-
rons (Fig. 5B). Interestingly, despite the differences in the aver-
age area of cortical and striatal neuronal somas (1.2; 220
4 versus 177  4 m2, n 	 526 and 477 neurons, respectively)
and especially between cortical and striatal astrocytes (2.5;
324  8 versus 796  30 m2, n 	 472 and 267 astrocytes,
respectively), themitochondrial concentrations in both types of
FIGURE 3. In situmonitoring of mitochondrial Ca2 buffering capacity in neurons and astrocytes from cortex and striatum. A–D, changes in [Ca2]i (i)
and in TMRM (ii; solid lines) or PMPI (ii; dashed lines) fluorescence in arbitrary units (A.F.U.). The solid or dashed line in i and ii depictsmeasurements performed
simultaneously in the same single cell. Representative cells with identical [Ca2]i kinetics were chosen (i) in order to allow comparison of changes in TMRM

and PMPI fluorescence (ii). Assay buffer contained 10mMpyruvate, and glucosewas replaced by 2mM 2-deoxy-D-glucose before the addition of oligomycin (3
M; O). FCCP addition (1 M; F) confirms full m collapse. R and r, Rmax and Rmin determinations, respectively. A (i),  , duration of the [Ca
2]i plateau (i.e.
apparent mitochondrial Ca2 buffering). A (ii),  , mitochondrial concentration. Up to 50 random single cells of each type were analyzed per experiment;
only a few are shown for clarity, being representative of n	 7 independent experiments.
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neurons as well as in both types of astrocytes is remarkably
similar (Fig. 5B). These results show that mitochondrial con-
centration is primarily governed by the cell type (neurons ver-
sus astrocytes) rather than by its region of origin (cortical versus
striatal).
To test whether in situ mitochondria of the different cell
types were being exposed to different rates of [Ca2]i elevation,
we performed experiments similar to those depicted in Fig. 3
but with the further addition of myxothiazol (2 M) after oligo-
mycin (Fig. 4). The underlying reasoning was that although oli-
gomycin allows mitochondrial Ca2 uptake, the combination
of oligomycin and a respiratory chain inhibitor (myxothiazol)
prevents it by collapsing m (17), thus allowing a measure-
ment of the rate at which [Ca2]i is rising inside cells, in close
analogy with removing mitochondria from the “test tube” and
measuring the rate at which Ca2 is being infused in isolated
mitochondria experiments (13). Indeed, with myxothiazol
present, m in both neurons and astrocytes rapidly collapsed
(Fig. 4, A–D (ii), solid lines; TMRM dequenching), and the
[Ca2]i elevation initiated with oligomycin progressed without
interruption until near Fura-4F saturation, showing the
absence ofmitochondrial Ca2uptake (Fig. 4,A–D (i); compare
with Fig. 3, A–D (i)). By means of nonlinear regression with
Equation 2, as detailed under “Experimental Procedures,” we
calculated the rate constant, Kexp, allowing comparisons of the
rate of [Ca2]i elevation among cell types. Two-factor
(region  cell type) ANOVA of this parameter (Fig. 5C)
revealed a significant region  cell type interaction (F(1,16) 	
14.5; p 	 0.002) as well as a significant main effect of the cell
type (neurons versus astrocytes; F(1,16)	 8.45; p	 0.010) and of
the brain region (cortical versus striatal; F(1,16) 	 11.2; p 	
0.004). These results show that mitochondria in cortical neu-
rons are exposed to a significantly higher rate of [Ca2]i eleva-
tion when compared with the other cell types (cortical astro-
cytes, striatal neurons, or striatal astrocytes) for which similar
rates were observed. Hence, the absence of differences in mito-
chondrial Ca2 buffering between cortical and striatal neurons
depicted in Fig. 5A is only “apparent.” Indeed, in order to buffer
for similar periods a faster rate of Ca2 elevation with identical
mitochondrial concentrations, cortical neurons should possess
mitochondria with higher Ca2 buffering capacities than stria-
tal neurons.
To allow comparisons of the present in situ mitochondrial
Ca2 buffering data with what should be expected if the mito-
FIGURE 4. Intracellular Ca2dynamics in neurons and astrocytes fromcortex and striatumunder conditionswheremitochondria are prevented from
buffering [Ca2]i. A–D, changes in [Ca
2]i (i) and in TMRM
 or PMPI (ii; solid or dashed lines, respectively) fluorescence in arbitrary units (A.F.U.). The solid or
dashed line in i and ii depicts measurements performed simultaneously in the same single cell. i, representative cells with identical [Ca2]i kinetics to allow
comparisons in ii. Oligomycin (O; 3M) andmyxothiazol (M; 2M) were added where indicated. FCCP (F; 1M) addition and in situ determination of Rmax and
Rmin (R and r, respectively) were performed at the indicated times for cells depicted by solid lines and slightly earlier for those shown by dashed lines (A and B,
10 min earlier; C and D, 5 min earlier). This time variation results from the need to anticipate and avoid excessive Fura-4F leakage to allow accurate [Ca2]i
calibration. Assay buffer contained 10mM pyruvate, and glucose was replaced by 2mM 2-deoxy-D-glucose before the addition of oligomycin (3M). A (i), Kexp,
the rate of [Ca2]i elevation. Up to 50 random single cells of each type were analyzed per experiment; only a few are shown for clarity, being representative of
n	 5 independent experiments.
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chondria were isolated, we calibrated the “apparent values” for
each cell type (Fig. 5A), dividing them by the respective average
mitochondrial concentrations (Fig. 5B) and multiplying by the
respective average rates of [Ca2]i elevation (Fig. 5C)  103.
Two-factor (region  cell type) ANOVA of the calibrated val-
ues (Fig. 5D) revealed a significant main effect of the cell type
(neurons versus astrocytes; F(1,24) 	 10.4; p 	 0.004) and of
brain region (cortical versus striatal; F(1,24) 	 18.4; p 
 0.001),
with no significant region cell type interaction (F(1,24)	 2.35;
p	 0.138). The observed power for the main effect of cell type
and of brain region was 87.1 and 98.4%, respectively. Meaning-
fully, these results provide original evidence that mitochondria
not only in neurons but also in astrocytes from striatal origin
exhibit a decreased Ca2 buffering capacity when compared
with their cortical counterparts.
Mechanisms Underlying in Situ Mitochondrial Ca2 Buffer-
ing Differences—Mitochondria have been shown to interact
with the endoplasmic reticulum (ER) in the regulation of intra-
cellular Ca2 signaling (22). Thus, a possible mechanism
underlying differences in in situmitochondrial Ca2 buffering
between cell typesmight involve heterogeneity in their ERCa2
levels and/or ER-mitochondria Ca2 signaling. To test this
hypothesis, we challenged cortical and striatal cells with 1 M
thapsigargin prior to the determination of mitochondrial Ca2
buffering capacity. Thapsigargin acutely and selectively arrests
ERCa2 pumps, depleting and preventing ERCa2 storage (23,
24). We consistently observed transient [Ca2]i elevations fol-
lowing acute exposure to thapsigargin in astrocytes but less
frequently in neurons (see supplemental Fig. 3 for representa-
tive tracings). Previous studies evidenced typically small Ca2
increases in neurons challenged with thapsigargin, detected
with the high affinity Fura-2 probe (25), which may escape
detection with the intermediate affinity Fura-4F in our experi-
ments. Although this suggests that ER stores may differ in neu-
rons and astrocytes, thapsigargin treatment did not signifi-
cantly (p  0.05) modify the mitochondrial Ca2 buffering
capacity of each cell type (as a percentage of respective control:
cortical neurons 	 97.3  5.8%, cortical astrocytes 	 92.4 
2.3%, striatal neurons 	 95.1  2.2%, striatal astrocytes 	
96.7 5.8%; n	 3 independent experiments), arguing against a
FIGURE 5.Apparent versus calibrated in situmitochondrial Ca2 buffering capacity in cortical and striatal neurons and astrocytes. A–D, factorial
ANOVA profile plots, depicting mean and S.E. for the different variables (named in graph titles) used in analysis of variance with two factors: cell type
(neurons or astrocytes; black or white circles, connected by solid or dashed lines, respectively) and region (cortical or striatal; left or right circles,
respectively). Associated statistical information is shown on the right of each graph (*, p 
 0.05; **, p 
 0.01; ***, p 
 0.001; observed power was
computed using 	 0.05). Shown are data from 5–7 independent experiments. A.U., arbitrary units; A.F.U., arbitrary fluorescence units. See “Results” for
a detailed description of data and statistics.
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major contribution of the ER in explaining differences in mito-
chondrial Ca2 buffering between cortical and striatal neurons
and astrocytes.
Differences in Ca2 buffering between isolated brain mito-
chondria mixtures have been previously associated with the
occurrence of permeability transition and/or the levels of mito-
chondrial cyclophilin D (26, 27). Thus, we tested whether
cyclosporin A (CsA; an inhibitor of mitochondrial permeability
transition that binds to cyclophilin D) influenced the differ-
ences in mitochondrial Ca2 buffering exhibited by intact neu-
rons and astrocytes. We performed experiments identical to
those described in the legend to Fig. 3, both in the absence
(control) and in the continuous presence of 1 M CsA, includ-
ing a 15-min preincubation period. Interestingly, results
depicted in Fig. 6 showed that this CsA treatment significantly
increased mitochondrial Ca2 buffering capacity in striatal but
not cortical astrocytes and not in neurons from either brain
regions. Still, because CsA is also known to inhibit calcineurin,
and thereby regulate mitochondrial phenomena such as frag-
mentation (28), we also tested the effect of FK506, which shares
the property of calcineurin inhibition with CsA but has no
effect on mitocondrial permeability transition (29). Cells were
preincubated for 15 min with FK506, which was kept through-
out the experiments at the previously used concentration of 0.6
M (28).We found no significant differences (p 0.05) inmito-
chondrial Ca2 buffering between control cells and those
where calcineurin was inhibited (as a percentage of respective
control: cortical neurons 	 96.4  3.2%, cortical astrocytes 	
95.8  2.4%, striatal neurons 	 103.9  3.5%, striatal astro-
cytes 	 93.6  4.2%; n 	 3 independent experiments). Taken
together, these findings suggest that the selective effect of CsA
on striatal astrocytes is unrelated to calcineurin inhibition but
rather reflects inhibition of permeability transition. Thus, an
increased propensity to undergo CsA-sensitive permeability
transition in striatal astrocytes is a likely mechanistic explana-
tion for their decreased mitochondrial Ca2 buffering capacity
when compared with cortical astrocytes.
DISCUSSION
The present study is the first to examine whether mitochon-
dria in neurons and astrocytes from cortex and striatum differ
in Ca2 buffering capacity. Here we describe a novel strategy
allowing in situmeasurements ofmitochondrial Ca2 buffering
in intact cells. In addition, we present evidence that mitochon-
dria in striatal neurons and astrocytes exhibit a decreased Ca2
buffering capacity when compared with their cortical counter-
parts. Also, we show that differences between neuronal and
astrocyticmitochondria are region-specific and thatmitochon-
drial Ca2 buffering differences between cortical and striatal
astrocytes are abolished with 1 M CsA. These results provide
additional insight into themechanisms of selective striatal neu-
rodegeneration and into the relative Ca2 vulnerability of neu-
ronal and astrocytic mitochondria, as discussed below.
Mitochondria are high capacity Ca2 buffering systems that
play a key role in protecting cells from Ca2-induced damage
(17, 30). Hence, differences in mitochondrial Ca2 buffering
are hypothesized to assist the selective vulnerability of cellular
populations in the brain. A previous study, using mitochondria
isolated from cortical and striatal homogenates, raised the
hypothesis that striatal mitochondria might be “supersensitive
to Ca2,” thus contributing for selective striatal vulnerability in
HD (2). However, data reflected a mixed nonsynaptic mito-
chondrial population in which the predominance of neuronal
(26) or glial (31) mitochondria is debatable. The ensuing ques-
tion of whether striatal mitochondrial vulnerability involves
neuronal or glial mitochondria or both has so far remained
unanswered.
Results in this study support the last possibility by showing
that mitochondrial Ca2 buffering capacity is decreased not
only in striatal versus cortical neurons but also in striatal versus
cortical astrocytes. This implies that striatal neurons, in addi-
tion to the vulnerability present in their ownmitochondria, are
paired with more vulnerable astrocytic partners than cortical
neurons. Also, our finding that 1 M CsA selectively increased
mitochondrial Ca2 buffering capacity in striatal astrocytes,
rendering it identical to that of cortical astrocytes, without
modifying neuronal mitochondrial Ca2 buffering, has impor-
tant implications. Indeed, it suggests that the ability of CsA to
protect striatal neurons in in vivoHDmodels (32) could be the
indirect consequence of reducing the mitochondrial vulnera-
bility of their astrocytic neighbors.
Vulnerable astrocytes may aggravate the susceptibility of
neuronal neighbors by failing to provide adequate support
under pathophysiological conditions (9, 11, 33). Mitochondrial
impairment in astrocytes may compromise protective astro-
cyte-neuron lactate trafficking and/or cause them to produce
diffusible reactive oxygen species that damage nearby neurons
(10, 34). Meaningfully, neurons rely on astrocytes for an effi-
cient clearance of extracellular glutamate, an activity shown
to be defective in HD astrocytes (35). We propose that defi-
cits in this and other energy-dependent astrocytic activities
will be aggravated in striatal astrocytes, since their Ca2-
vulnerable mitochondria should more frequently arrest ATP
synthase or even reverse its activity, thus decreasing ATP
availability.
FIGURE 6. Effect of cyclosporin A on the mitochondrial Ca2 buffering
capacity of intact neurons and astrocytes fromcortex and striatum. Bars,
mean and S.E. of “apparentmitochondrial Ca2 buffering capacity,” assessed
in experiments identical to those described in Figs. 3 and 5A, and performed
in the absence (control; white bars) or presence of cyclosporin A (1 M CsA,
black bars). Data are from three independent experiments andwere analyzed
by t test comparison between CsA-treated cells and their respective controls,
evidencing a significant (p
 0.05) effect in striatal astrocytes but not in other
cell types (n.s., nonsignificant).
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ATP synthase reversal allowsmitochondria to delaym col-
lapse, provided that cells have sufficient glycolytic ATP. Thus,
mitochondria may appear to be more resistant to injury in cells
with abundant glycogen stores, as we have previously shown for
HD cellular models (8). Given the limited glycogen availability
in neurons as opposed to astrocytes (36), the phenomenon of
mmaintenance byATP synthase reversalmay better conceal
earlier mitochondrial damage in astrocytes than in neurons,
thus acting as a major confounding factor when comparing
mitochondrial function in these cell types. To avoid this, we
inhibited the use of glycogen stores and ATP synthase reversal
in our experiments with intact neurons and astrocytes. For the
purpose of data comparison, it should be noted that glycogen
stores are typically unavailable in isolated mitochondria
experiments.
Isolated brain mitochondria are mixtures of neuronal and
glial mitochondria. These mixtures are heterogeneous in
response to Ca2, as shown within nonsynaptic fractions (37),
and when comparing synaptic with nonsynaptic fractions (26,
27), strengthening the hypothesis that neurons and glia differ in
Ca2 buffering capacity. Presently, it is still unfeasible to isolate
functional neuronal and glial mitochondria from the adult
brain, narrowing the pursuit of this hypothesis to studies with
primary cultures of brain cells. A previous study addressed this
hypothesis using suspensions of permeabilized cells and evi-
denced that mitochondria in cerebellar neurons (1 DIV) buff-
ered less Ca2 than in cortical astrocytes (10 DIV) (38). How-
ever, given the different regions under study for neurons
(cerebellum) and astrocytes (cortex), it cannot be generalized
that neuronal mitochondria buffer less Ca2 than astrocytic
mitochondria. Indeed, within the same region (cortex or stria-
tum), we saw the opposite, namely that neuronal mitochondria
bufferedmoreCa2 than astrocyticmitochondria. Still, this did
not apply across regions, sincemitochondria in striatal neurons
did not buffer more Ca2 than in cortical astrocytes, highlight-
ing the cellular and regional specificity of mitochondrial Ca2
buffering differences.
Addressing the mechanisms underlying mitochondrial Ca2
buffering differences and considering possible mitochondria-
ER interactions in Ca2 signaling (22), we tested whether selec-
tively depleting and arresting ERCa2pumpswith thapsigargin
modified in situmitochondrial Ca2 buffering. Because thapsi-
gargin did not significantly affectmitochondrial Ca2 buffering
in any of the four cell types, it is unlikely that ER heterogeneity
explains their differences in mitochondrial Ca2 buffering
capacity. This finding by no means undermines the physiolog-
ical relevance of ER-mitochondria Ca2 signaling, particularly
at low [Ca2]i, being probably explained by thewide disparity in
the amounts of maximal Ca2 accumulation by the two
organelles and by ER saturation occurring before [Ca2]i
reaches the set point for mitochondria net uptake. Although
intact cells may differ in Ca2 handlingmechanisms other than
the mitochondria (e.g. pumps, buffers, and exchangers), in our
experimental conditions, we have introduced calibrations for
the rate of Ca2 elevation (Kexp) in the different cell types when
mitochondria Ca2 buffering was selectively inhibited, which
yielded a measurement of net [Ca2]i elevation considering
Ca2 handling mechanisms (entry and extrusion pathways)
other than the mitochondria.
Alternative mechanisms may involve a differential mito-
chondrial sensitivity to permeability transition. We tested
whether mitochondrial Ca2 buffering was modified by CsA
(inhibitor of permeability transition and calcineurin), and by
FK506 (calcineurin inhibitor). The absence of effect of FK506
suggests that calcineurin activity does not modify mitochon-
drial Ca2 buffering, possibly because calcineurin activation is
subsequent to mitochondrial depolarization (28), when the
driving force for Ca2 buffering is exhausted. Moreover, it
highlights the inhibition of permeability transition rather than
calcineurin as the prevailing effect of CsA in our experiments.
Therefore, given that 1 M CsA abolished the differences in in
situmitochondrial Ca2 buffering between cortical and striatal
astrocytes, our results show that mitochondria in striatal astro-
cytes exhibit an increased propensity to undergo a CsA-sensi-
tive form of permeability transition. The lack of a CsA (1 M)
effect over the other cell types suggests the occurrence of CsA-
insensitive forms of permeability transition (39, 40). However,
it is also possible that higher concentrations of CsA might be
required for an effect to be observable, as suggested from recent
data with isolated synaptic mitochondria, where 5M but not 1
M CsA increased mitochondrial Ca2 buffering capacity (27).
Unfortunately, testing of this possibility in intact neurons is
hampered by their vulnerability to greater than 1 M CsA con-
centrations (39, 41). The need for high CsA concentrations in
order to inhibit mitochondrial permeability transition may be
associated with high levels of the CsA target, cyclophilin D
(CypD) (27). Indeed, CypD levels were shown to be inversely
correlated with the mitochondrial resistance to permeability
transition, namely throughout brain development (42). Mean-
ingfully, the highest levels of brain CypD protein were found in
1-day-old rats and progressively decreased, so that at 10 days of
age, CypD expression became nearly identical to that of mature
3-month-old animals (Fig. 4d in Ref. 42). These findings suggest
that the relative differences in mitochondrial Ca2 vulnerabil-
ity between 1DIV cerebellar neurons and 10DIV cortical astro-
cytes (38) might change considerably when both cell types have
10DIV.Moreover, the stabilization ofCypD expression after 10
days of age (42) supports the modeling of brain mitochondrial
Ca2 buffering with mature cultures of brain cells (11–13 DIV
in the present study). Indeed, sufficient time in culture is essen-
tial for neurons to develop a network of processes containing
mitochondria that is probably heterogeneous with respect to
that in the cell body (43–45).
The decreased mitochondrial Ca2 buffering of striatal ver-
sus cortical neurons in the present study reflects neuronalmito-
chondria as a whole. In light of recent findings with synaptic
versus nonsynaptic cortical mitochondria (26), it would be
interesting to compare the Ca2 vulnerability of synaptic mito-
chondria in striatal and cortical neurons, since it may contrib-
ute to differences in the present study and influence patholog-
ical synaptic dysfunction in HD (46) as well as the greater
susceptibility of striatal neurons to toxic insults (1, 6, 47). We
recently compared the distribution and trafficking of in situ
mitochondria within the processes of cortical and striatal neu-
rons and found similar fractional occupations but faster mito-
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chondria movement in cortical neurons.3 Although similar
mitochondrial fractional occupation in processes is in agree-
ment with the similar overall mitochondrial concentrations
reported in the present study, the differences in mitochondrial
movement speed raise the interesting hypothesis that mito-
chondria in cortical neurons may more rapidly and efficiently
handle Ca2 buffering needs in distant processes by means of
faster trafficking.
In summary, the present study shows for the first time that
the increased vulnerability of striatal versus cortical mitochon-
dria toCa2 loads resides in both intact neurons and astrocytes.
Mitochondria in striatal astrocytes have an increased propen-
sity to undergoCsA-sensitive permeability transition, position-
ing the striatum at greater risk for disturbed neuron-astrocyte
interactions and probably contributing to selective striatal
demise in HD and other neurological disorders. The selective
effect of 1 M CsA over striatal astrocytes suggests that in vivo
neuronal sheltering with this compound may indirectly result
from astrocytic protection.
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